Park Place Capital Corp Has $669,000 Stock Holdings in Johnson & Johnson $JNJ

Park Place Capital Corp trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,291 shares of the company’s stock after selling 484 shares during the period. Park Place Capital Corp’s holdings in Johnson & Johnson were worth $669,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. G&S Capital LLC boosted its stake in shares of Johnson & Johnson by 1.4% during the 2nd quarter. G&S Capital LLC now owns 4,995 shares of the company’s stock worth $763,000 after buying an additional 69 shares during the last quarter. Capital Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 2.2% during the 2nd quarter. Capital Investment Advisors LLC now owns 434,565 shares of the company’s stock worth $66,380,000 after buying an additional 9,532 shares during the last quarter. Bennett Selby Investments LP boosted its stake in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Bennett Selby Investments LP now owns 18,125 shares of the company’s stock worth $2,769,000 after buying an additional 567 shares during the last quarter. Presper Financial Architects LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $278,000. Finally, Raleigh Capital Management Inc. lifted its stake in Johnson & Johnson by 7.3% in the 2nd quarter. Raleigh Capital Management Inc. now owns 14,777 shares of the company’s stock valued at $2,257,000 after purchasing an additional 1,005 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America raised their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Thursday, August 21st. Finally, The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $181.40.

Johnson & Johnson Stock Up 0.3%

Johnson & Johnson stock opened at $185.99 on Thursday. The stock has a market cap of $447.92 billion, a P/E ratio of 19.89, a P/E/G ratio of 2.36 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $186.56. The company’s 50-day moving average price is $175.45 and its two-hundred day moving average price is $162.51.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.